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Abstract: Vitamin K is a multifunctional micronutrient implicated in age-related diseases such as
cardiovascular diseases, osteoarthritis and osteoporosis. Although vitamin K-dependent proteins
(VKDPs) are described to have a crucial role in the pathogenesis of these diseases, novel roles have
emerged for vitamin K, independently of its role in VKDPs carboxylation. Vitamin K has been shown
to act as an anti-inflammatory by suppressing nuclear factor κB (NF-κB) signal transduction and
to exert a protective effect against oxidative stress by blocking the generation of reactive oxygen
species. Available clinical evidences indicate that a high vitamin K status can exert a protective
role in the inflammatory and mineralization processes associated with the onset and progression
of age-related diseases. Also, vitamin K involvement as a protective super-micronutrient in aging
and ‘inflammaging’ is arising, highlighting its future use in clinical practice. In this review we
summarize current knowledge regarding clinical data on vitamin K in skeletal and cardiovascular
health, and discuss the potential of vitamin K supplementation as a health benefit. We describe the
clinical evidence and explore molecular aspects of vitamin K protective role in aging and age-related
diseases, and its involvement as a modulator in the interplay between pathological calcification and
inflammation processes.
Keywords: vitamin K; vitamin K-dependent proteins; cardiovascular diseases; skeletal health;
inflammaging; pathological calcification; inflammation
1. Introduction
Vitamin K is a family of naphthoquinone compounds comprising K1 (phylloquinone) and several
forms of K2 (MKs, menaquinones). Phylloquinone is synthesized exclusively by plants, algae, and some
species of cyanobacteria. Menaquinones are mainly produced by obligate and facultative anaerobic
bacteria [1], with long side chains (MK7 to MK13) with the exception of MK4, that is not a common
product of bacterial synthesis, but is considered to be of animal origin based on its tissue-specific
conversion from phylloquinone [2]. In terms of structure, both forms are characterized by the presence
of a common polar, hydrophilic 2-methlyl-1,4-naphtoquinone ring (menadione, vitamin K3) and a
hydrophobic polyisoprenoid side chain that can vary in length and bond saturation. Vitamin K1 has a
phytyl side chain containing only one unsaturated bond. Vitamin K2 family (MK-n) is divided in a
series of isoprenologs where n is the number of prenyl units in the isoprenoid side chain. Vitamin K has
been first reported for its role as a cofactor for the microsomal enzyme γ-glutamyl carboxylase (GGCX)
ensuring the correct function of vitamin K-dependent hepatic clotting factors. The posttranslational
protein modification that converts specific glutamic acid residues (Glu) into γ-carboxyglutamate (Gla),
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is crucial for the function of vitamin K-dependent proteins (VKDPs), also known as Gla proteins.
However, the health benefits of this micronutrient were shown to extend beyond coagulation, and
to have an extra-hepatic role ensuring the correct function of several extra-hepatic VKDPs. These
have been described to play different roles in both physiological and pathological processes such as
tissue mineralization, neuroprotection, energy metabolism, inflammation and cellular growth and
survival. Also, the potential use of vitamin K2 in the prevention and clinical treatment of cancer was
recently reviewed [3]. This multifunctional vitamin has been implicated in chronic age-related diseases
such as cardiovascular diseases, osteoporosis and osteoarthritis [4]. More recently, a novel role has
been disclosed for vitamin K as an antioxidant and anti-inflammatory, independent of its activity as
a cofactor for GGCX. The function of VKDPs associated to these emerging functions of vitamin K
is now starting to be explored. Vitamin K status has been associated with lower concentrations of
inflammatory markers in vivo [5], and proposed to exert an anti-inflammatory role by suppressing
nuclear factor κB (NF-κB) signal transduction [6,7]. Also, a protective effect against oxidative stress
was suggested for this micronutrient through blocking of reactive oxygen species (ROS) generation [8]
(Figure 1).
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Figure 1. Vitamin K roles in health and disease. Vitamin K function as a co-factor for γ-glutamyl 
carboxylase enzyme (GGCX) essential for the γ-carboxylation of target vitamin K-dependent proteins 
(VKDPs), but also independent of GGCX as an anti-inflammatory and antioxidant agent. 
Uncarboxylated (uc) protein forms of VKDPs, such as GRP, MGP, OC and Gas6, have been implicated 
in several pathological processes occurring in multiple age-related diseases, while the γ-carboxylated 
form of these proteins (c) are known to have a health protective role. Glu, glutamic acid; Gla, γ-
carboxyglutamic acid; IKK, nuclear factor κB kinase; NF-κB, nuclear factor κB. 
Several chronic inflammatory and mineralization-related diseases have been associated with 
vitamin K deficiency, namely cardiovascular disease (CVD), chronic kidney disease (CKD) [9], 
osteoarthritis (OA) [10] and osteoporosis. Since these are highly prevalent age-related health 
conditions, and both inflammation and pathological mineralization are associated with the aging 
Figure 1. Vitamin K roles in health and disease. Vitamin K function as a co-factor for γ-glutamyl
carboxylase enzyme (GGCX) essential for the γ-carboxylation of target vitamin K-dependent proteins
(VKDPs), but also independent of GGCX as an anti-inflammatory and antioxidant agent. Uncarboxylated
(uc) protein forms of VKDPs, such as GRP, MGP, OC and Gas6, have been implicated in several
pathological processes occurring in multiple age-related diseases, while the γ-carboxylated form of
these proteins (c) are known to have a health protective role. Glu, glutamic acid; Gla, γ-carboxyglutamic
acid; IKK, nuclear factor κB kinase; NF-κB, nuclear factor κB.
Several chronic inflammatory and mineralization-related diseases have been associated with
vitamin K deficiency, namely cardiovascular disease (CVD), chronic kidney disease (CKD) [9],
osteoarthritis (OA) [10] and osteoporosis. Since these are highly prevalent age-related health conditions,
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and both inflammation and pathological mineralization are associated with the aging process, a new
concept of vitamin K involvement in aging and ’inflammaging’ is arising. Given the growing amount
of data regarding vitamin K and VKDPs functionality and beneficial effects, it is not surprising that
it could be considered a super micronutrient used in clinical practice as a health supplement in the
near future. In this work, we thoroughly review available data regarding clinical studies involving the
evaluation of vitamin K in skeletal and cardiovascular health, highlighting that definitive conclusions
are still warranted to clearly impose vitamin K supplementation as a health benefit. We also address
the role of vitamin K in aging conditions such as functional decline, disability, sarcopenia and frailty,
affecting the elderly in an aging society. Simultaneously, we explore the protective role of vitamin K
in aging and age-related diseases, through its involvement as a modulator in the interplay between
pathological calcification and inflammation processes.
2. Vitamin K and Health: Evidences from Clinical Studies
Besides its role in maintaining normal blood coagulation, vitamin K and VKDPs play an important
role in human bone metabolism and soft tissue physiology, and are mechanistically associated with the
onset and progression of several age-related chronic diseases [10–13].
A chronic low-grade pro-inflammatory state and calcification of connective tissues have been
implicated in age-related diseases such as cardiovascular disease (CVD) and osteoarthritis (OA).
Both conditions are highly prevalent in the aging population and, as the number of patients will
continue to rise, this constitutes a major worldwide challenge for our health system. Currently there
are no effective treatments available to prevent, stop, or even restrain CVD and OA progression.
Treatments are targeted to relieve symptoms, prevent complications and reduce the risk of recurrence
or worsening. Inflammation and pathological calcification not only play a key role in CVD and OA, but
are also involved in a complex interplay, ultimately leading to disease progression. Understanding the
underlying molecular mechanisms driving these processes will lead to the discovery of new biomarkers
and therapeutic strategies for these age-associated diseases. Research efforts on the role of vitamin K
and VKDPs in diseases of aging have been mainly focused on the action of matrix Gla protein (MGP)
and osteocalcin (OC). Gla-rich protein (GRP) is a VKDP, and was recently shown to have a dual capacity
to act as an anti-inflammatory agent and an inhibitor of pathological calcification in the articular and
vascular system. Novel and more efficient diagnostic and therapeutic options are urgently needed to
lower the burden and the associated health care costs of CVD and OA in the aging population.
Several population-based studies and randomized trials focusing on the association of different
forms of vitamin K and CVD and OA outcomes, are available or presently ongoing. Furthermore, an
association between CVD and OA has been highlighted in recent years. In a cohort study involving 2156
participants with hip and/or knee OA aged over 55 years, OA disability was significantly associated
with mortality and serious CVD events [14]. A previous population-based cohort study, involving
1163 OA patient follow-up for a median of 14 years, also reported that increased mortality in people
with OA, was largely due to CVD causes [15].
2.1. Circulating Biomarkers to Evaluate Vitamin K Status
Considering the natural vitamers of vitamin K, K1 and K2, vitamin K status is dependent on
both the dietetic intake and intestinal bacterial synthesis. According to the Panel on Dietetic Products,
Nutrition and Allergies (NDA) of the European Food Safety Authority, none of the available biomarkers
of vitamin K intake or status are considered suitable to derive dietary reference values for vitamin K.
The assessment of vitamin K nutritional status in population and clinical-based studies is still of crucial
importance to unveil the role of vitamin K in human health and age-related chronic diseases [16].
In terms of vitamin K status, the literature unanimously considers that there is no “gold standard”
biomarker to measure vitamin K sufficiency or deficiency. Instead, vitamin K status has been evaluated
using multiple biomarkers, each reflecting a different aspect of vitamin K intake, storage, bioavailability
and function. Common direct methods include the quantification of urinary vitamin K1 metabolites [17]
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and of circulating forms of vitamin K1 and K2 [18]. According with a recent review [19], most of the
available data on circulating vitamin K is based on direct measurements of circulating K1, which is
still considered by many researchers a global indicator of vitamin K status. One limitation of this
measurement is that it only reflects vitamin K short-time intakes, due to the short half-life of the K1
vitamer [20]. Most of these available studies, using direct quantification methods, are focused on the
assessment of dietary vitamin K levels, instead of its association with health and pathologic conditions.
Still, limited information is available in the literature for plasma menaquinones, mostly because (except
for MK4) their concentrations are much lower and generally not detectable in circulation, unless large
quantities are consumed [19].
On the other hand, a considerable number of clinical studies describe the use of indirect methods,
measuring circulating markers representing uncarboxylated VKDPs, namely OC and MGP, to reflect
extra-hepatic vitamin K status, or study the effect of vitamin K supplementation, and/or its association
with a particular health condition. The choice of the appropriate biomarker for a specific clinical
study needs to be addressed based on the research question to be explored, together with the available
scientific evidences sustaining its association with the particular health condition. Several assays
measuring different forms of OC and MGP fractions in circulation have been developed [21,22],
and validated in clinical assays for their ability to reflect vitamin K status [23]. Clinical studies
focused on CVD have chosen to use circulating levels of desphospho-uncarboxylated matrix gla
protein (dp-ucMGP), since this was found to be the best biomarker to reflect vitamin K status [23]
and vascular calcification (VC). Indeed, several randomized controlled studies have shown the effect
of vitamin K supplementation in lowering circulating levels of dp-ucMGP [24–26]. In a randomised,
double-blind, placebo-controlled trial to investigate the effect of MK-7 supplementation, the authors
found a dose-dependent decrease of uncarboxylated MGP concentrations [27], supporting the choice
of dp-ucMGP as a non-invasive marker of vitamin K status. Also, studies in healthy subjects to
evaluate changes in systemic vitamin K status showed a decrease in dp-ucMGP levels, resulting from
vitamin K supplementation, and an increase following treatment with a vitamin K antagonist (VKA,
coumarin derivatives such as warfarin) [23]. An observational cohort study, involving 160 prevalent
haemodialysis (HD) patients [28], and a relatively small study enrolling a total of 60 kidney transplants
recipients [25], have both confirmed that VKA therapy was associated with higher dp-ucMGP levels.
Interestingly, a study measuring dp-ucMGP in seven HD patients switching from VKA to fondaparinux
(an indirect factor Xa inhibitor), showed that stopping VKA treatment is associated with a rapid
reduction of dp-ucMGP concentrations, to levels observed in HD patients not treated by VKA [29].
Osteocalcin is a VKDP synthetized in bone and circulating uncarboxylated form (ucOC) has
been described to reflect low vitamin K status [30]. In clinical studies addressing bone health, ucOC
is usually selected as a biomarker of vitamin K status [31–33]. Also, circulating undercarboxylated
prothrombin, known as PIVKA-II (protein induced by vitamin K absence or antagonism–II), is a
functional marker to access vitamin K status in response to vitamin K restriction, such as to VKAs [34].
Nevertheless, currently available PIVKA-II commercial assays have been reported as lacking sensitivity
to detect variation in vitamin status associated with healthy populations [19].
2.2. Vitamin K Status and Skeletal Health
Low vitamin K status has been associated with multiple co-morbidities, functional decline and
disability in older adults, especially in those with associated age-related diseases such as OA and
osteoporosis [11,35].
2.2.1. Functional Decline and Disability
In a cross-sectional and longitudinal analysis enrolling 1089 community-dwelling older adults
from the Health ABC Study, a lower vitamin K status measured by plasma K1 levels and dp-ucMGP,
was associated with worse lower-extremity function over 4–5 years of follow-up [36]. In the same
analysis, dp-ucMGP was not consistently associated with lower-extremity function, suggesting a
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direct effect of vitamin K on skeletal muscle, independent of its function as a co-factor of GGCX. In
a following study of the same Health ABC cohort, the authors evaluated the association between
vitamin K status and incident mobility limitation and disability. Although no underlying mechanism
is proposed, the results suggest the involvement of vitamin K in the disabling process associated with
aging. Older adults with lower levels of plasma K1 were found to be more prone to develop mobility
limitation and disability, compared to those with higher circulating levels [37]. In a prospective study
involving 13 years of follow-up of 644 community-dwelling adults from the Longitudinal Aging
Study Amsterdam (LASA) cohort, low baseline vitamin K status (high levels of circulating dp-ucMGP)
was associated with a higher frailty index score in older aging people [38]. A previous longitudinal
analysis in this LASA cohort (13 years follow-up), showed that a lower status of vitamin K was
associated with lower grip strength and calf circumference, reinforcing the association of the physical
component in the development of frailty. This highlights the importance of vitamin K to prevent and
slow down the development of frailty in an aging population and precludes its beneficial use as a
nutritional supplement.
2.2.2. Osteoporosis
The effect of vitamin K supplementation on bone metabolism has been evaluated in several
randomized clinical trials. Most of these studies were conducted with postmenopausal women
with osteoporosis, and generally concluded that both vitamin K1 and K2 had a protective effect on
bone health, by increasing bone strength and reducing bone turnover, while decreasing the risk of
fractures [35,39–43]. Nevertheless, some inconsistencies are still found in the literature. A study
performed within the Danish Osteoporosis Prevention Study (DOPS) including a cohort of 2016
perimenopausal women, concluded that vitamin K1 supplementation had no effect in bone mineral
density and fracture risk [44]. In another study performed in the community-based Hordaland Health
Study, a low intake of vitamin K1 was associated with an increased risk of fractures, while K2 showed
no association [45]. Regarding this issue, a study comparing absorption and efficacy of K1 and MK7
showed that both forms were well absorbed but MK7 was able to induce a more complete carboxylation
of OC in bone [46]. In fact, high doses of vitamin K2 have been shown to be effective in the prevention
and treatment of osteoporosis, although most of these studies were initially done in Japan [41,47–50].
A randomized clinical trial comprising a total of 4378 women with osteoporosis, concluded that the
beneficial effect of supplementation with 45 mg/day menatetrenone (MK4) was only demonstrated in
postmenopausal women with advanced osteoporosis [51]. A meta-analysis including 19 randomized
controlled trials and encompassing 6759 participants was conducted to estimate the effect of vitamin
K2 for the prevention and treatment of osteoporosis in postmenopausal women [52]. The authors
conclude that K2 treatment was able to improve vertebral bone mineral density (BMD) and reduce
fracture risk in osteoporotic postmenopausal women, although no effect was seen in postmenopausal
women without osteoporosis. A systematic review and a meta-analysis including 36 randomized
controlled trials with a total of 11,112 participants addressing the effect of vitamin K supplementation
on BMD and fractures in adults was recently published. Most of the trials included in the analysis
used the MK4 form of vitamin K2 (45 mg/day), although many also used vitamin K1 and some MK7
at various dosages [53]. From this study, vitamin K supplementation appears to have no effect on
vertebral fracture outcomes and little effect on BMD, for postmenopausal and osteoporotic patients.
In fact, whether the effect of vitamin K supplementation, inducing a decrease in circulating ucOC,
leads to improvement of bone quality and to reductions in BDM loss and fractures in postmenopausal
healthy women, remains a matter of divergence and debate in the literature [54]. This could be due to
limitations such as small study samples, which difficult the confirmation of the role of vitamin K in
bone pathology. In a large-scale interventional study, the Japanese Osteoporosis Intervention Trial-03
(JOINT-03), a total of 1983 osteoporotic women (mean age 75.3 years) were randomly allocated into two
groups, one including 931 patients treated with vitamin K2 (45 mg/day) and risedronate (2.5 mg/day)
and the other (n = 943) taking risedronate alone (2.5 mg/day). In both groups, the incidence of fractures,
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changes in BMD, height and ucOC concentration, was evaluated over a 2-year follow-up. The authors
concluded that, in terms of fracture prevention, there was no difference between both treatments [55].
Also, given the variability of vitamin K2 supplementation doses included in the different studies, and
the different conclusions, it is reasonable to suggest that different formulations of vitamin K appear to
have different levels of potency, and that higher doses might be necessary to fully carboxylate OC.
Recently, an open-labelled prospective cohort study evaluated the effect of escalating doses of MK4 on
the improvement in OC carboxylation. The study was conducted in postmenopausal women with
osteoporotic fractures, and showed that supplementation with 5 or 45 mg/day of MK-4 reduced ucOC
to levels usually reported in young and healthy adults. The authors also concluded that higher doses
of MK4 were more effective, with no major side effects [56].
2.2.3. Osteoarthritis (OA) and Rheumatoid Arthritis (RA)
Evidences from preclinical studies have suggested a role for vitamin K in OA prevention. Clinical
studies on the effects of vitamin K on OA are very limited and most addressing only vitamin K1. The
first indication of an association between low plasma levels of vitamin K and increased prevalence
of knee and hand OA features came from an observational analysis involving 672 participants from
the Framingham Offspring cohort [57]. The same results were reported in another observational
study using a survey information on dietary intake obtained from 719 subjects of the elderly Japanese
population [58]. A longitudinal analysis with 1180 subjects from the Multicenter Osteoarthritis (MOST)
Study concluded that subclinical levels of plasma K1 were associated with an increased risk of OA
development [10]. Consistent with these results, another longitudinal study involving participants
from the Health ABC Study [59] showed that subjects with very low plasma K1 were more likely to
have articular cartilage loss over the three years follow-up [11].
VKDPs, namely OC, MGP and more recently GRP, have been shown to be associated with OA.
A single-arm clinical study involving 25 Japanese patients with bilateral knee OA determined ucOC
serum levels, and suggested that ucOC could be a useful marker for evaluating the pathophysiological
condition of knee OA [60]. Results from in vitro and ex vivo experiments have shown that
uncarboxylated MGP (ucMGP) was associated with increased mineralization in OA cartilage, suggesting
that vitamin K deficiency may contribute to abnormal mineralization in OA [61]. Data from an
observational cross-sectional study, involving 26 arthritis patients and 30 controls, showed that the ratio
of synovial to serum ucMGP was significantly higher in inflammatory arthritis versus non-inflammatory
arthritis. However, although higher levels of serum ucMGP were found in arthritis patients when
compared with controls, the results did not reach statistical significance [62].
Also, 791 knee OA participants were drawn from the Health ABC Study for a cross-sectional
analysis, and 523 for a 3-year longitudinal observational study, to investigate the association of K1 with
structural features of knee OA in older community-dwelling adults. Individuals with elevated levels
of dp-ucMGP at baseline were found to be more likely to have osteophytes, bone marrow lesions,
subarticular cysts, and meniscal damage. Participants with very low plasma K1 had a 1.7- and 2.6-fold
higher odds of worsening cartilage and meniscal damage over 3 years, although dp-ucMGP was not
associated with progression of any OA features [11]. Based on these findings, the authors suggested
the possible involvement of vitamin K in OA independent of its function in MGP carboxylation.
Interventional studies assessing the effects of vitamin K1 supplementation in OA and RA are
available. A 3-year randomized controlled trial, involving 378 participants assessing the effect of vitamin
K1 supplementation (500 µg/day) on radiographic hand OA in older adults, failed to find a beneficial
effect in hand OA progression as compared to the placebo group [63]. Recently, a small double-blind
placebo-controlled trial, enrolling 58 patients with rheumatoid arthritis and including vitamin K1
supplemented (10 mg/day) and placebo groups, concluded that after the 8 weeks follow-up, there were
no significant differences between the two groups regarding blood biomarkers of inflammation or
disease severity [64].
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In fact, mineralization and inflammatory processes have been shown to be intimately linked in a
feed-back loop that will ultimately lead to OA development and progression [65–67]. In addition to
MGP and OC, GRP was recently associated with the OA pathophysiology. Evidences from pre-clinical
studies have shown a predominance of the undercarboxylated forms of GRP in cartilage and synovial
membrane from OA patients [68,69]. GRP was suggested as a novel factor linking the two main
pathological processes associated with OA, mineralization and inflammation.
In a study enrolling 158 female patients suffering from rheumatoid arthritis (RA) [70], vitamin K2
(MK4) supplementation was shown to be associated with a reduction of inflammation and disease
activity. A cross-sectional prospective study enrolling 84 RA patients was performed in order to
elucidate the therapeutic role of MK7. After 3 months, the supplemented group showed a significant
reduction in markers of inflammatory status and a reduction in disease activity score [71].
Of note, several in vitro studies have been supporting a novel function for vitamin K, as an
anti-inflammatory agent independently of its role as a cofactor of GGCX, which might also be an
alternate pathway influencing joint health (further detailed below) [7,72,73].
Although no definitive information on cause-and-effect relation can be derived from the available
studies, overall, they strongly indicate a beneficial role of vitamin K in bone and cartilage health, and
further suggest a protective effect of vitamin K supplementation in OA. Further and larger sample
clinical interventional studies, on the effect of vitamin K in OA prevention, are needed to evaluate the
efficacy of the different vitamin K forms as therapeutic agents and to unveil their role as modulators in
the interplay between mineralization and inflammation, driving the disease progress.
2.3. Vitamin K Status and Cardiovascular Diseases (CVD)
Several lines of evidence from preclinical studies have established the involvement, at tissue and
systemic level of vitamin K in VC, mainly through carboxylation of two vitamin K-dependent proteins:
MGP and GRP. In the last 10 years, a growing number of observational and longitudinal clinical studies
on the relation between vitamin K status and cardiovascular health have arisen. Dietary vitamin K
is believed to decrease the risk of CVD, but inconsistent results are reported. This may be due to
different effects of vitamin K vitamers (K1 and K2), although most studies do not include both. In fact,
cross-sectional studies reported an inverse association between K2 intake and incidence of coronary
heart disease (CHD) and coronary calcification [74,75], consistent with a protective role of dietary
vitamin K against the incidence of cardiovascular events. These studies included an investigation of
vitamin K1 and several subtypes of K2. In an observational cross-sectional study enrolling 564 Dutch
women, high intake of K2 was associated with decreased coronary calcification, but K1 intake was
not [74]. Previously, the Rotherham Study also investigated both K1 and K2 intake, but relations of
the different K2 subtypes with coronary calcification were not addressed. In this study, a protective
effect of dietary K2 intake against CHD in older men and women was suggested, with no consistent
association of K1 intake with CHD, mortality or aortic calcification [75]. Further, a prospective study
using data from a cohort of 16,057 elderly women followed for 8.1 years, showed that a higher dietary
vitamin K2 intake was significantly associated with a lower incidence of CHD, and mainly driven by
MK7, MK8 and MK9 subtypes [76].
In the majority of the reported studies, the dp-ucMGP is used to assess the cross-sectional relation
between circulating vitamin K status and CVD, since it has been considered as the unique circulating
MGP form reflecting, at extra-hepatic tissue level, vitamin K status and function [27]. As recently
reviewed [77,78], several clinical observational studies have shown an association between increased
levels of dp-ucMGP with VC and CVD-related outcomes. These studies were mainly performed in
specific high-risk population groups, such as CKD patients [79], diabetic and hypertension patients [80],
or long-term warfarin anticoagulant therapy users [81]. Overall, a growing amount of evidence from
clinical observational studies indicates an association between vitamin K status and higher levels of
circulating dp-ucMGP, with a higher cardiovascular risk, including higher coronary artery calcification
(CAC), increased peripheral arterial calcification, higher carotid-femoral pulse wave velocity and
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increased arterial stiffness. Two cross-sectional studies have shown that subjects with the highest
dp-ucMGP had a positive association with increased arterial stiffness, which is also an independent risk
factor for CVD [82,83]. Also, a longitudinal study enrolling 577 community dwelling older participants
in the Longitudinal Aging Study Amsterdam (LASA), without prevalent CVD at baseline, showed that
after a mean follow-up of 5.6 ± 1.2 years, higher plasma dp-ucMGP was correlated with a significant
higher CVD risk [84]. A prospective longitudinal cohort study including 635 participants drawn
from the Health ABC Study [59] was performed to determine the association between plasma K1 and
dp-ucMGP with the risk of CVD over a period of 12 years [12]. The results from this study showed
that low plasma K1 was a risk factor for CVD in older individuals treated for hypertension, but no
association was demonstrated in the non-treated group. In a recent meta-analysis, including a total of
11 prospective cohort studies involving 33,289 patients, the association between dp-ucMGP and the
risk of cardiovascular events and mortality was assessed. The results indicated that higher circulating
levels of dp-ucMGP, indicative of vitamin K insufficiency, were significantly associated with a higher
CVD and total mortality risk. As a conclusion, the authors further suggest that dp-ucMGP may
serve as an independent risk of mortality, although emphasizing that more and larger-populations
studies are needed to confirm this association [13]. However, in a post-menopausal cross-sectional
study, where dp-ucMGP was reduced by vitamin K1 supplementation, changes in dp-ucMGP did
not correlate with CAC [85]. Also, in a general healthy population a case-cohort study involving 11
years of follow-up, showed that high dp-ucMGP levels, reflecting poor vitamin K status, were not
associated with an increase in CHD or stroke risk [86]. Interestingly, a prospective cohort in healthy
postmenopausal women showed that higher circulating levels of K1 were unexpectedly associated
with increased prevalence of CAC. The authors suggested that the K1 status obtained from dietary
intake in this observational study, might not be able to sustain a protective effect on CAC [87].
In a randomized trial (n = 244, mean age 59.5 ± 3.3 years), 3-years of supplementation with
a nutritional dose of natural MK7 (180 µg/day) was shown to decrease arterial stiffness in healthy
postmenopausal women, especially in a subgroup of women with high local carotid artery stiffening [88].
A low vitamin K status in CKD patients has been associated with a high prevalence of VC and
cardiovascular mortality [9,89]. In 2014, a prospective, randomized, single-blinded intervention study
was performed, including 200 chronic haemodialysis patients, to evaluate the effect of high-doses
of MK7 supplementation [24]. This study, showing a dose-dependent decrease in dp-ucMGP by
MK7 supplementation, was further confirmed in a more recent clinical intervention trial with MK7,
including 50 haemodialysis patients [90]. The conclusions will be useful for further studies on larger
interventional trials, addressing the effect of vitamin K supplementation on CVD progression and
mortality in the haemodialysis population.
Several clinical studies are currently ongoing to evaluate the efficacy of vitamin K supplementation
in CVD progression. The VitaVasK is a prospective, randomized study that will include 348
haemodialysis patients, and aims to study the effect of vitamin K1 in reducing VC progression
in CKD patients [91]. The VitaK-CAC trial is a double-blind, randomized, placebo-controlled trial,
currently investigating the effect of MK7 supplementation in patients with coronary artery disease,
and also aiming to evaluate the effect on disease progression [92].
So far, the conclusions drawn from clinical studies are still quite limited by the small sample
number and the substantial associated heterogeneity. More robust clinical trials, including a larger
number of patients, addressing the effect of the different forms of vitamin K supplementation to
improve cardiovascular calcification/stiffness, thereby reducing the risk of cardiovascular events and
promoting long-term cardiovascular health, are urgently needed.
In fact, some answers are soon to be expected from ongoing clinical trials. The Aortic Valve
Decalcification trial (AVADEC) is a randomised, placebo-controlled study that will examine the effect
of MK-7 on progression of aortic valve calcification (AVC) for a period of at least 24 months [93]. The
study is planned to include a total of 400 patients with an AVC score above 300 but without aortic
valve stenosis. Half of the patients will be randomized to placebo treatment, and the other half for
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supplementation with MK-7. If positive effects are shown from this interventional study, this could
represent new treatment options to prevent progression of AVC.
Of note, a recent observational prospective study has highlighted the potential role of circulating
GRP as a novel biomarker of VC. In this study enrolling 80 type 2 diabetic patients with CKD stages
2–4, total GRP serum levels were found to be associated with deterioration of renal function and to be
an independent risk factor of VC in this population [94]. In this study circulating GRP was measured
using a recently published sandwich ELISA system, able to detect total GRP, independently of its
γ-carboxylation state [95]. Although this was the first study exploring the relation between GRP
circulating levels and VC at clinical level, the results showed that decreased serum GRP could be a
clinical predictor of pathological calcification in CKD, with promising and broader applications as a
new marker for cardiovascular calcifications.
3. Vitamin K in the Interplay between Calcification and Inflammation in Age-Related Diseases.
Evidences from Pre-Clinical and Clinical Studies
Aging is a well-established major risk factor for all chronic diseases and syndromes associated
with old age. Vitamin K has been suggested to play a protective role in aging and age-related
diseases. Highly prevalent diseases such as CVD and OA still represent a major health challenge in our
aging society worldwide. CVD and OA are chronic low-grade inflammatory diseases that have been
associated with increased risk of mobility disability and frailty, in the elderly. Also, vitamin K has been
implicated in chronic diseases that lead to mobility disability and frailty. Although a beneficial effect of
vitamin K has been suggested to prevent and ameliorate these age-related conditions, its underlying
mechanism of action is not yet known.
The development of a pro-inflammatory status, characterized by high levels of inflammatory
markers present at local and systemic levels, is a common characteristic associated with aging
and age-related diseases such as CVD, type 2 diabetes, CKD, cancer, osteoporosis, OA, frailty,
sarcopenia and several neurological disorders. The human aging process characterized by a chronic,
low grade proinflammatory state was coined in 2000 as ‘inflammaging’ [96]. More recently, a
related concept termed ‘garb-ageing’ was introduced. This concept emphasizes the decline in
cell autophagy, that becomes impaired with aging. ‘Garb-ageing’ refers to the accumulation of
“molecular garbage” consisting of endogenous/self, misplaced/altered macromolecules resulting
from damaged/dead cells or organelles (cell debris), ultimately leading to the continuous activation
of inflammasome in macrophages [97]. Multiple stressors and damaging agents such as ROS,
DNA damage agents and telomere loss, can trigger cell senescence, which is characterized by a
quiescent cell state with a pro-inflammatory phenotype [98]. This altered phenotype is known as
senescence-associated secretory phenotype (SASP) and involves the production of high levels of
pro-inflammatory cytokines, chemokines, growth factors and matrix metalloproteinases (MMPs). With
aging or in a pathologic context, senescent cells are known to accumulate in tissues, promoting local
and systemic inflammation [96,98]. The SASP has been recently described to promote age-related
pathologies such as OA and CVD [99–101], and to be a significant risk factor for morbidity and mortality
in the elderly (reviewed in [99]) (Figure 2).
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Figure 2. Schematic representation of vitamin K involvement in ’inflammaging’ and age-related
diseases. ’Inflammaging’ and its associated senescence-associated secretory phenotype (SASP) can be
triggered by stress conditions such as reactive oxygen species (ROS), DNA damage and telomerase
loss, resulting in increased oxidative stress, mitochondrial dysfunction, cell senescence and apoptosis.
All these processes contribute to an increased low-grade inflammatory status at tissue and systemic
levels. Decreased vitamin K levels have been associated to increased aging processes and age-related
disorders, by interfering with theγ-carboxylation of VKDPs such as Gas6 and GRP involved in apoptosis
and pathological calcification, and by modulating inflammation, oxidative stress and mitochondrial
dysfunction independently of its activity as co-factor for γ-glutamyl carboxylase (GGCX). Abs, apoptotic
bodies; OA, osteoarthritis; CVD, cardiovascular diseases.
Mitochondrial function has been reported to be reduced with aging in terms of adenosine
triphosphate (ATP) production and respiratory chain activity [102,103]. Oxidative stress induces
damage to mitochondrial DNA resulting in altered abundance and function of mitochondrial proteins.
A considerable body of literature has reported that an increase in mitochondrial dysfunction can lead
to the establishment of a low-level chronic and systemic inflammation status, resulting in increased
oxidative stress, which promotes a vicious inflammatory cycle that modulates most chronic age-related
diseases (reviewed in [104,105]). In this context of mitochondrial pathology, there are still no studies
available in mammalian cells addressing a direct effect of vitamin K. Nevertheless, a study in Drosophila
proposes vitamin K2 as a promising compound to treat mitochondrial pathology. In this study, MK4
can act as a mitochondrial electron carrier, like ubiquinone, facilitating ATP production, rescuing
mitochondrial defects and restoring its function [106].
All these structural and genomic changes involving several factors such as cell senescence,
oxidative stress and inflammatory mediators, lead to an increase in apoptotic processes which have
also an important role in several chronic age-related diseases. Apoptosis has been for long described to
be of pathophysiological significance in CVD and OA [107] (Figure 2). Results from in vitro and ex vivo
studies have shown that articular chondrocytes-derived apoptotic bodies contribute to the pathologic
cartilage calcification and extracellular matrix degradation, observed in OA and aging [108,109].
Apoptotic bodies were shown to be able to perform the same role as matrix vesicles, promoting the
formation of calcium phosphate (CaP) crystals. The same is reported in vascular smooth muscle cells
(VSMCs) where apoptotic bodies are known to act as nucleating structures for CaP formation [110].
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CaP crystals also have a role at systemic level, as part of circulating calciprotein particles (CPPs)
and mineralization-competent extracellular vesicles (EVs). Several studies have demonstrated the
toxicity of CaP nanocrystals and their ability to promote pro-inflammatory reactions, which, in turn,
induce pro-calcific responses in a cycle were mineralization triggers inflammation and vice-versa.
Mineralization and inflammation have been shown to play a key role in the pathophysiology of
CVD and OA. The complex crosstalk between both processes leads to an amplified response that
ultimately contribute to disease progression. Nowadays, it‘s currently accepted that highly complex
mechanisms regulate the formation, maturation and consequent pathogenicity of CaP nucleation
sites. At the same time, soft tissue mineralization is an active and naturally occurring multifactorial
process that must be actively inhibited [111]. This emphasises the concept that inhibition of CaP crystal
formation and maturation should bring important results in the prevention and management of these
age-related diseases.
In the context of apoptosis, the VKDP Gas6 has been shown to exert anti-apoptotic effects
on endothelial and VSMCs [112–114], by binding and activating the receptor tyrosine kinase
Axl [112,115,116]. More recently, an in vitro study using primary cultured rat VSMCs, showed
that treatment with vitamin K2 was able to inhibit VSMC calcification by preventing apoptosis through
restoration of the Gas6/Axl/Akt pathway [117], further indicating a potential contribution of vitamin K
for the treatment of CVD.
The anti-inflammatory activity of vitamin K has been demonstrated in several in vitro and animal
studies. In a study using human primary cultured fibroblasts challenged with the lipopolysaccharide
(LPS) endotoxin, MK4 was found to suppress IL-6 production, with higher efficiency than vitamin K1.
The same results were obtained in THP-1 human macrophages and murine RAW264.7. In this study,
all vitamin K forms (K1, MK3, MK4 and MK7) were found to supress LPS-induced expression of IL-6
similarly. Furthermore, the anti-inflammatory effect of vitamin K was shown to be independent of its
Gla formation activity. After treatment of the cells with LPS, MK4 reduced the activation of NF-κB,
and inhibited IKKα/β phosphorylation [7]. Also, vitamin K1 supplementation was shown to supress
the inflammation state induced by LPS in rats [72]. Of note, several clinical studies have demonstrated
that vitamin K status in humans is inversely correlated with circulating inflammatory markers. In a
cross-sectional study enrolling 379 healthy men and postmenopausal women (mean age 68 ± 6 years;
58.5% women), plasma vitamin K1 was found inversely correlated with IL-6 and C-reactive protein
(CRP), considered a marker of systemic inflammation, although no association was found for serum
%ucOC. Nevertheless, no differences were noted in the 3-year follow-up of patients receiving vitamin
K1 supplementation, relatively to the concentrations of inflammatory biomarkers. The lack of effect of
vitamin K1 supplementation on circulating cytokines obtained in this placebo-controlled trial, was
suggested to be due to the healthy status of this cohort [118]. In another cross-sectional community
based-cohort analysis, enrolling participants from the Framingham Offspring Study (n = 1381; mean
age 59 ± 8 years), circulating levels of vitamin K1 and K1 intake, were both found inversely associated
with IL-6 and osteoprotegerin inflammatory markers [5]. Interestingly, %ucOC was not associated with
overall inflammation, supporting the previous in vitro evidences showing that vitamin K modulates
inflammation by a mechanism independent of its role in Gla formation.
Consistently with previous cross-sectional analyses in Caucasian adults [118], an observational
study performed in 662 community-dwelling adults (mean age 62 ± 10 years) from the Multi-Ethnic
Study of Atherosclerosis (MESA), without clinical apparent CVD, showed that serum K1 was
significantly and inversely associated with several circulating inflammatory markers namely IL-6, CRP
and intercellular adhesion molecule 1 (ICAM-1) [119]. In a cohort analysis of the Health ABC including
1163 older adults (mean age 74 ± 3 years), those with lower circulating levels of K1 at baseline, had
also higher circulating IL-6 levels, further supporting the potential anti-inflammatory effect of vitamin
K at systemic level [12].
A double-blind randomized clinical trial, involving 244 healthy postmenopausal women, receiving
either placebo or MK7 for 3 years, showed that MK7 supplementation did not influence circulating
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inflammatory markers. Nevertheless, IL-6 and high-sensitivity C-reactive protein (hsCRP) correlated
with vascular vitamin K status (measured by dp-ucMGP) and arterial stiffness at baseline [88].
Contrarily, in a cross-sectional prospective study involving RA patients on MK4 supplementation for 3
months, a significant reduction in inflammatory markers was observed [70]. Overall, the number of
clinical studies aiming to evaluate the benefits of the use of vitamin K supplementation in modulating
inflammation is still limited. From the available results we suggest that patients with inflammatory
diseases, rather than healthy elderly, would be a more adequate population to study the efficacy of
vitamin K supplementation on the inflammatory state. This subject clearly merits further investigation.
As a final note on the relation between vitamin K and inflammation, the potential role of GRP
should be further explored at clinical level. Although the association of circulating total GRP [95],
with vascular calcification has been recently shown in a small observational prospective study in
type 2 diabetic patients with CKD, no indications were yet disclosed relatively to the association with
inflammatory markers [94]. Several in vitro and ex vivo evidences have demonstrated that this VKDP
has a dual capacity to act as an inhibitor of VC and as an anti-inflammatory [69,120]. This role was
reinforced when supplementation of CPPs isolated from CKD stage 5 patients with γ-carboxylated
GRP (cGRP), were able to rescue the calcification/osteogenic differentiation and inflammatory status
induced in VSMCs [95].
Recently, low vitamin K status has been associated with multiple co-morbidities, functional
decline, disability and frailty in older adults [37,121], especially in those with associated OA and
CVD [11,122]. In addition, inflammation accelerates ageing in individuals with multimorbidity, and
further promotes the functional limitation and disability in the elderly [123]. Several cross-sectional
studies describe an association between inflammation and frailty in older adults [124–126]. High levels
of circulating pro-inflammatory cytokines, such as CRP, tumor necrosis factor alpha (TNF-α), and
IL-6 were shown to promote sarcopenia, a syndrome related with frailty and characterized by muscle
breakdown and increased risk of muscle mass and strength loss [126,127]. In a population consisting
of 1323 older community-dwelling adults (mean age 74.6 ± 2.8 years) drawn from the Health ABC
cohort study, plasma vitamin K1 was inversely associated with IL-6 and knee pain. Also, dp-ucMGP
was found to be positively associated with IL-6 and mobility disability in this cohort [36].
Importantly, vitamin K1 and K2 have been shown to have antioxidant properties in cultured
neurons and oligodendrocytes, independently of its role in the carboxylation of VKDPs [8,128]. This
study showed that cell death, caused by oxidative stress was able to be prevented, by inhibiting activation
of 12-lipoxygenase, which could represent an alternative anti-inflammatory mechanism associated
with vitamin K. In vertebrates, vitamin K epoxide reductase complex subunit 1 (VKORC1)-like
1 (VKORC1L1), the paralogous enzyme of the VKORC1, is described to play a fundamental role
in intracellular antioxidation, by protecting cells from oxidative damage of membrane intrinsic
proteins [129]. Furthermore, two kinetic studies showed that vitamin K1-hydroquinone is a strong
antioxidant, 10–100 times more potent when compared with other biological radical scavengers such
as vitamin E (α-tocopherol), and ubihydroquinone-10 [130], suggesting a role in preventing lipid
peroxidation in biological systems. In another study, aiming to test the effect of the vitamin K cycle on
lipid peroxidation in rat liver microsomes, vitamin K1 and K2 (MK4) were shown to prevent lipid
peroxidation in a dose-dependent way, with similar activity for both vitamers, and with warfarin
counteracting the vitamin K effect [131]. Based on these results, dietary intake of vitamin K may
together with other phytonutrients, strengthen cellular defence against oxidative stress.
4. Conclusions
It is currently known that the range of vitamin K action is far beyond the scope of blood coagulation.
Although several available studies support a protective role for vitamin K in aging and age-related
conditions such as cardiovascular disease, osteoarthritis and osteoporosis, the real evidence of the
benefit of vitamin K supplementation is still controversial, since most of the available studies are
observational and only a few randomized trials are currently available. Nevertheless, an important
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conclusion has been drawn relatively to its safe use as a health benefit, since no adverse effect or
documented toxicity for K1 or MK4 and MK7 has ever been reported for individuals consuming
higher amounts of vitamin K. Even when doses above the recommended daily allowance (RDA) of 75
micrograms vitamin K (Commission Directive 2008/100/EC) were used, no hypercoagulable state was
observed. Based on this, a Tolerable Upper Intake Level is not available.
Regardless of the available evidences clearly supporting a beneficial health effect of vitamin K, its
underlying mechanism of action specialty regarding its novel and less explored functions as molecule
with anti-inflammatory and antioxidant properties, is not yet known. This is particularly relevant
in age-related diseases and in aging conditions such as functional decline, disability, sarcopenia and
frailty, affecting the elderly in an aging society. In fact, aging societies represent a major economic
challenge for health care systems, and diet supplements promoting healthy aging and improving the
prognosis of age-related diseases are urgently needed to be implemented in clinical practice.
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AVC Aortic valve calcification
BMD Bone mineral density
CAC Coronary artery calcification
CaP Calcium phosphate mineral
CHD Coronary heart disease
CKD Chronic kidney disease
CPPs Circulating calciprotein particles
CRP C-reactive protein
CVD Cardiovascular disease
cGRP γ-Carboxylated Gla-rich Protein
dp-ucMGP Desphospho-uncarboxylated Matrix Gla Protein
EVs Extracellular vesicles
GGCX Gamma-glutamyl carboxylase
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ROS Reactive oxygen species
SASP Senescence-associated secretory phenotype
TNF-α Tumor necrosis factor alpha
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ucOC Uncarboxylated Osteocalcin
VC Vascular calcification
VKA Vitamin K antagonist
VKDPs Vitamin K-dependent proteins
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